REDWOOD CITY, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that the United States Patent and Trademark Office has granted OncoMed its first U.S. patent on its MAbTrap™ antibody display technology, one of the company's novel antibody platform technologies. OncoMed's MAbTrap™ technology enables the rapid identification of monoclonal antibodies that bind a particular target or set of targets, and bind such target or targets with high affinity and specificity. OncoMed has used the patented technology to identify and/or optimize novel antibodies, including proprietary bispecific antibodies, and demonstrated the activity of these antibodies in preclinical studies.
The new patent, U.S. Patent No. 8,551,715, relates to methods of producing libraries of cells that express membrane-bound antibodies or other specific binding agents on their surface, and methods of identifying the cells in such libraries that express an antibody or other agent having the desired binding characteristics. The patented methods include novel mammalian cell display methods. Related patent applications are currently pending in the U.S., Europe, Japan, China, and a number of other countries worldwide. The new patent and related applications are all solely owned by OncoMed.
Read more: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=795899
Via CNN Money:
FORTUNE -- A few weeks ago I wrote a column for the magazine about how most health apps don't work very well, aren't reaching those most in need, and -- besides -- counter to all claims that technology will save health care, several proven solutions involve real people, interacting with other real people, in real life. My goal was to call B.S. on what I find to be an all-too-pervasive Valley-ism: that smartphone software that tracks steps or helps photograph food or replaces your doctors visit will revolutionize medicine and change the world. No. For the most part, health apps are selling to the least needy but most willing buyers: rich people who care about being healthy. My colleague Dan Primack, who is out in the Bay Area this week, calls it "a particularly insular narcissism" in Silicon Valley, which seems exactly right.
AtheroMed announces completion of patient enrollment in the EASE study evaluating the Phoenix Atherectomy System in treating PAD
MENLO PARK, CA – October 2, 2013 – AtheroMed, a developer of innovative technologies for treating peripheral artery disease (PAD), announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances (VIVA) conference in Las Vegas.
MALVERN, Pa., August 19, 2013 – TetraLogic Pharmaceuticals, a biopharmaceutical company
Santa Clara, CA, July 24, 2013 — ProteinSimple today introduced the FluorChem R system as the next member of the FluorChem product family. The FluorChem R system is a fully integrated, multimode gel and Western blot imager with chemiluminescent, fluorescent, and infrared detection capabilities.
ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes
San Diego, California, July 10, 2013 — ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company’s largest existing investors – Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).
Judy Twist shares with Lisa her success with the program Prevent.
Two big names in lifestyle change development for diabetes prevention are joining forces to bring their technologies to more participants. Omada Health offers its Prevent program that combines a curriculum, coaching, and social support to motivate people with pre-diabetes to change dangerous aspects of their lifestyles. Viridian Health Management, meanwhile, has been rolling out its My Weigh 2 Prevent Diabetes program in more than 30 states. Both are based on the curriculum of the National Diabetes Prevention Program (National DPP) which was developed as part of an NIH study supported by the CDC that showed that modest lifestyle modifications can lead to significant reduction in the chance of developing diabetes. While Viridian’s program relies on face-to-face coaching at clinics and community centers, Omada’s is an online program, so the partnership will help channel people toward the programs more appropriate for them.
GUEST MENTOR Sean Duffy, CEO and co-founder of Omada Health: No entrepreneur can — or should — go it alone. But beyond hiring some teammates in the trenches, you’ll also need a handful of people working with you from the sidelines. Your advisers and board of directors are there to provide the high-level input that is difficult to get when you’re in the weeds.
Tornier Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Over-Allotment Option
AMSTERDAM--(BUSINESS WIRE)-- Tornier, N.V. (NASDAQ: TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, announced today the closing of the previously announced underwritten public offering of 8.05 million ordinary shares at a public offering price of $16.15 per ordinary share. The shares sold include 1.05 million ordinary shares sold pursuant to the option to purchase additional shares granted by Tornier and certain existing shareholders to the underwriters, which was exercised in full. Tornier received net proceeds from this offering of approximately $78.8 million, after deducting underwriters' discounts and commissions and estimated expenses.